FDA’s Plasma Program Data Lacks Cohesion

 Informal study hampered by greater than anticipated participation of COVID-19 patients.

The U.S. Food and Drug Administration designed a plasma program to try and speed along potential research into COVID-19 vaccination and prevention. They expected 5,000 participants in total. When 64,000 coronavirus patients volunteered to receive plasma from those who recovered from COVID-19, the FDA did not have the resources to keep their findings consistent across hospitals.

All available data was sent to peer reviewed journals across the country, but it will be difficult for scientists to interpret the data without the cohesion and consistency found in more formal, well-planned studies. Scientists hope they will be able to decipher something, but more tests and studies will be required regardless of their findings.

As the Lord Leads, Pray with Us…

  • For the Food and Drug Administration as they work to end the spread of the pandemic.
  • That scientists would be granted clear minds and creative thinking in researching the coronavirus.
  • That President Trump would aid their healing efforts with the power granted to him.

Sources: AP


Back to top